A Non-Randomized, Open Label, Controlled, Dose-Escalation, Phase I Clinical Trial to Evaluate the Safety, Reactogenicity and Immunogenicity of One or Two Administrations of Candidate Rabies mRNA Vaccine CV7202 in Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 05 Nov 2019
Price : $35 *
At a glance
- Drugs CV-7202 (Primary) ; Rabies vaccine
- Indications Rabies
- Focus Adverse reactions; First in man
- Sponsors CureVac
- 29 Oct 2019 Planned number of patients changed from 130 to 50.
- 25 Oct 2018 New trial record
- 23 Oct 2018 According to a CureVac media release, first patient has been enrolled in this trial.